- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA approves first spinal tether implant for correcting childhood scoliosis | ||
| Fr | Agilent unveils combination real-time cell imager and analyzer following ACEA acquisition | ||
| Fr | Monopar files for $40M IPO to test chemo side effect drug | ||
| Fr | Chutes & Ladders-GlaxoSmithKline poaches Merck KGaA exec to run U.S. pharma | ||
| Fr | Alector, Prevail trade blows over alleged misuse of confidential information | ||
| Do | How nematode worms could inspire safer opioid use | ||
| Do | EuroBiotech Report-Autolus delay, Novartis sale, Sonnet deal, Y-mAbs and the U.K. | ||
| Do | EuroBiotech: More Articles of Note | ||
| Do | MacroGenics, Incyte's PD-1 med to face off with Merck's Keytruda in a first for cancer R&D | ||
| Do | In conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capital | ||
| Do | V-Wave nabs FDA breakthrough designation for its heart pressure shunt implant | ||
| Do | Ultragenyx snags option on antisense startup GeneTx | ||
| Do | Y-mAbs ramps up head count in post-IPO hiring spree | ||
| Do | AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival | ||
| Mi | Treating glioblastoma with a Ziopharm drug and IL-12 gene therapy | ||
| Mi | ZipLine's wound closure alternative outperforms staples, sutures in two studies | ||
| Mi | Regeneron's Praluent sidekick moves the needle on 'bad' cholesterol | ||
| Mi | FDA cancer office taps Syapse for real-world evidence development | ||
| Mi | Zeldin joins Immunovant as CMO months after Acceleron split | ||
| Mi | D&D bags $137M to fund midphase Alzheimer's, Parkinson's trials | ||
| Mi | Renovacor bags $11M to push precision medicine for rare heart disease | ||
| Di | Xontogeny's Landos Biopharma reels in $60M to ramp up IBD program | ||
| Di | Datavant, PCORnet to build real-world data network spanning 60M patients | ||
| Di | Deciphera soars as phase 3 cancer data tee up FDA filing | ||
| Di | Novartis sells phase 3 rare disease drug to Pharming |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
